In other solid tumors (e.g., ovarian or breast), CXCL9 is a favorable prognostic biomarker that indicates that the cancer will respond to immune checkpoint inhibitor therapy and is associated with longer survival in some cases [64,65]. This evidence concerns the gene CXCL9 and cancer.